CN111956535A - Conditioner composition and preparation method and application thereof - Google Patents
Conditioner composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN111956535A CN111956535A CN201911405762.9A CN201911405762A CN111956535A CN 111956535 A CN111956535 A CN 111956535A CN 201911405762 A CN201911405762 A CN 201911405762A CN 111956535 A CN111956535 A CN 111956535A
- Authority
- CN
- China
- Prior art keywords
- composition
- oil
- vegetable oil
- cannabidiol
- components
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 85
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 48
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 40
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims abstract description 30
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims abstract description 30
- 229950011318 cannabidiol Drugs 0.000 claims abstract description 30
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims abstract description 30
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims abstract description 30
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 24
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000007901 soft capsule Substances 0.000 claims abstract description 24
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 24
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 24
- 229940046009 vitamin E Drugs 0.000 claims abstract description 24
- 239000011709 vitamin E Substances 0.000 claims abstract description 24
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 20
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 20
- 229940110767 coenzyme Q10 Drugs 0.000 claims abstract description 20
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 20
- 235000020944 retinol Nutrition 0.000 claims abstract description 20
- 239000011607 retinol Substances 0.000 claims abstract description 20
- 229960003471 retinol Drugs 0.000 claims abstract description 20
- 239000008158 vegetable oil Substances 0.000 claims abstract description 17
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 12
- 239000000284 extract Substances 0.000 claims abstract description 12
- 244000025254 Cannabis sativa Species 0.000 claims abstract description 9
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims abstract description 7
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims abstract description 7
- 235000009120 camo Nutrition 0.000 claims abstract description 6
- 235000005607 chanvre indien Nutrition 0.000 claims abstract description 6
- 239000011487 hemp Substances 0.000 claims abstract description 6
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 5
- 239000010460 hemp oil Substances 0.000 claims description 33
- 239000003921 oil Substances 0.000 claims description 24
- 235000019198 oils Nutrition 0.000 claims description 24
- 239000002775 capsule Substances 0.000 claims description 18
- 108010010803 Gelatin Proteins 0.000 claims description 13
- 229920000159 gelatin Polymers 0.000 claims description 13
- 239000008273 gelatin Substances 0.000 claims description 13
- 235000019322 gelatine Nutrition 0.000 claims description 13
- 235000011852 gelatine desserts Nutrition 0.000 claims description 13
- 235000005979 Citrus limon Nutrition 0.000 claims description 11
- 244000131522 Citrus pyriformis Species 0.000 claims description 11
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 7
- 230000003078 antioxidant effect Effects 0.000 claims description 7
- 235000013399 edible fruits Nutrition 0.000 claims description 7
- 240000000950 Hippophae rhamnoides Species 0.000 claims description 5
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims description 3
- 230000007368 endocrine function Effects 0.000 claims description 3
- 239000008169 grapeseed oil Substances 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 3
- 239000008347 soybean phospholipid Substances 0.000 claims description 3
- 244000144725 Amygdalus communis Species 0.000 claims description 2
- 235000011437 Amygdalus communis Nutrition 0.000 claims description 2
- 239000008168 almond oil Substances 0.000 claims description 2
- 239000010495 camellia oil Substances 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000020238 sunflower seed Nutrition 0.000 claims description 2
- 239000010497 wheat germ oil Substances 0.000 claims description 2
- 241000218236 Cannabis Species 0.000 claims 3
- 244000170916 Paeonia officinalis Species 0.000 claims 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 abstract description 17
- 229940083466 soybean lecithin Drugs 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 14
- 230000008832 photodamage Effects 0.000 abstract description 9
- 230000003647 oxidation Effects 0.000 abstract description 6
- 238000007254 oxidation reaction Methods 0.000 abstract description 6
- 230000007774 longterm Effects 0.000 abstract description 4
- 230000008439 repair process Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 230000002411 adverse Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 18
- 238000010438 heat treatment Methods 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- 230000032683 aging Effects 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 238000005303 weighing Methods 0.000 description 11
- 240000004308 marijuana Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000736199 Paeonia Species 0.000 description 6
- 206010051246 Photodermatosis Diseases 0.000 description 6
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000008845 photoaging Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000037380 skin damage Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 235000008697 Cannabis sativa Nutrition 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000009621 actinic keratosis Diseases 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 208000007287 cheilitis Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 208000005775 Parakeratosis Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010041303 Solar dermatitis Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000003465 angular cheilitis Diseases 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 description 1
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 description 1
- QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108010020410 methionine sulfoxide reductase Proteins 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a conditioner composition, a preparation method and application thereof. The composition disclosed by the invention comprises industrial hemp extract or cannabidiol, vitamin E, retinol, soybean lecithin, coenzyme Q10, vegetable oil and the like. The main components of the composition have a synergistic effect after compatibility, the bioavailability is high, the oxidation resistance is obviously improved, the composition has a good anti-aging effect, and the composition can effectively relieve skin inflammation and repair skin photodamage. Can be made into soft capsule, has stable quality, safety and no adverse side effect, can be orally taken or externally used, and can be used as conditioner for long term use.
Description
Technical Field
The invention belongs to the field of cosmetics, and relates to a conditioner composition, and a preparation method and application thereof.
Background
Cannabis is often used to assist in the treatment of certain advanced absolute conditions (cancer, aids), to stimulate appetite, relieve pain, to relieve neurological symptoms such as glaucoma and epilepsy, migraine, and bipolar mood swings, to relieve nausea in chemotherapy patients.
The human life generally goes through three stages of growth, maturity and aging (aging). The old age is the last stage of life and is the process of walking down a slope. During the aging stage of the human body, various organs, tissues and systems are changed. But the skin and appendages are the most likely to change in appearance. The most obvious changes of aging of people after the age of 40-50 are that hair changes from black to grey, skin changes from smooth to dull and loose, age spots appear, subcutaneous fat is reduced and denatured, skin elasticity is reduced, and skin is dry and thin. Skin aging is divided into two types, one is inherent aging, also called natural aging or endogenous aging, which is caused by genetic factors and non-resistant factors (the endocrine and immune functions of the body change along with the aging of the body); the other is exogenous aging caused by environmental factors such as ultraviolet rays, smoking, wind blowing, chemical contact and the like, wherein the long-term repeated irradiation of ultraviolet rays in sunlight is the most important factor influencing skin aging in the environment, and the factor is also called photoaging.
Endogenous aging is inevitable in the human development process, effective measures cannot be taken at present, and exogenous skin aging caused by ultraviolet rays can be prevented. The main mechanism of photoaging is that various components in the skin can induce the generation of active oxides after absorbing the energy of ultraviolet rays, directly attack cell membranes, cause lipid peroxidation, exhaust intracellular antioxidant enzymes, and accelerate the skin aging process. Meanwhile, the active oxide can also stimulate signal conduction in cells, induce skin fibroblasts to synthesize matrix metalloproteinase, and degrade various matrix components including collagen and elastin, so that the specific clinical expression and pathological change of the photoaging skin are formed.
Sunlight can cause skin damage in addition to photoaging. Wherein, the biological effect caused by the infrared ray is mainly a thermal effect, the skin can be hyperemic and form red spots after being irradiated by the infrared ray, and the skin can feel causalgia when the temperature is raised to 45 ℃. Erythema can be rapidly removed, and pigmentation can occur after repeated times; the biological effect of ultraviolet light is mainly a photochemical effect, and the photon flow with higher energy level causes the denaturation of nuclear protein and some enzymes in cells. After a latency period of 6-8 hours following irradiation, cellular changes occur and symptoms appear, including dry skin pain, shrinking epidermis, and even blistering and desquamation. Chronic, multiple exposures can cause solar keratosis (actinic keratosis) of the skin and mucous membranes, manifested by thickening of single or multiple flat-topped cornified layers, sometimes nodular, freckle-like or keratodermic, at exposed sites such as the forehead, cheek, nose tip, lips, eyelids, conjunctiva, and histopathological examination of the epithelial lining with parakeratosis, hyperkeratosis and abnormal keratosis, and loss of polarity of cell arrangement (see solar dermatitis). This is a precancerous change that may progress to skin cancer.
The main approach to reducing photoaging and photodamage is to resist oxidation: scavenging free radicals in vivo blocks the antioxidant pathway.
Most of the anti-aging products on the market at present are prepared by combining food or extracts of traditional Chinese medicines, have the function of enhancing the functions of human bodies to a certain extent, but the using effect is not ideal, and the anti-aging effect needs to be enhanced. Some of the existing anti-aging products use industrial components with strong oxidation resistance to achieve good anti-aging effect, take effect quickly in a short time, but are extremely harmful to human bodies after being used for a long time; some anti-aging products are added with vitamin antioxidants, but the products have poor stability and side effects after long-term use, for example, although vitamin E has anti-aging effect, if more than 100 mg of vitamin E is taken orally every day and is continuously applied for more than 6 months, gastrointestinal dysfunction, angular stomatitis, myasthenia, cheilitis can appear, hypoglycemia, thrombophlebitis, high blood fat and cholesterol can be caused, and the like. On the other hand, most of the existing products on the market have single function, although most of the products have certain antioxidation and anti-aging effects, for example, products containing vitamin E, vitamin C, superoxide dismutase, methionine sulfoxide reductase A, human cell protection protein, recombinant Trx-TAT-hMsrA fusion protein and other components have certain antioxidation effect, but the products can not repair damaged skin. When the skin is seriously damaged by light, urea ointment and Utrel are commonly used, but the drugs have great side effects and cannot be used for a long time. It is therefore desirable to develop a product that is effective, long-term, highly resistant to oxidation, and capable of repairing photodamaged skin.
Cannabidiol (CBD) is a non-toxic phenolic substance with high added value extracted from cannabis sativa leaves and can be used in medicines, cosmetics and health foods. Developed countries such as Israel, the United states, the United kingdom and the like have used the raw materials and developed various specific medicines and cosmetics. CBD is a non-addictive component in marijuana, can block the influence of THC on human nervous system, has pharmacological activities of antispasmodic, antirheumatic arthritis, antianxiety and the like, and also has reports on the aspects of antioxidation, anti-aging and photodamage repair, but the effect of singly using Cannabidiol (CBD) is not ideal.
Disclosure of Invention
The invention aims to provide a conditioner composition which has high oxidation resistance, can effectively repair skin photodamage, can be orally taken and externally used, and has good effects of resisting aging, lightening melanin, resisting inflammation, repairing photodamage, improving sleep and the like.
In view of the above objects, the present invention provides a composition comprising industrial cannabis extract or cannabidiol, vitamin E, retinol, soy lecithin, coenzyme Q10 and vegetable oil.
In some embodiments, in the above composition, the composition comprises, in mass percent:
the sum of the components is 100 wt%;
the Cannabidiol (CBD) may be a chemically synthesized product, a biologically synthesized product, a plant extract or prepared in other ways; preferably, the cannabidiol of the invention is a plant extract, and the plant extract part can be stem, flower, leaf, root and/or seed hulls of industrial Cannabis sativa l;
the industrial hemp extract contains 30-99% of cannabidiol by mass percentage;
preferably, the industrial hemp extract contains 50 to 99% of cannabidiol by mass percentage, more preferably 60 to 99% of cannabidiol by mass percentage, and particularly preferably 95 to 99% of cannabidiol by mass percentage.
Preferably, the industrial cannabis extract is a broad-spectrum cannabis oil, wherein the broad-spectrum cannabis oil is an industrial cannabis oil which mainly contains cannabinoids such as cannabidiol, cannabidivarin, cannabigerol and tetrahydrocannabinoid and contains active ingredients such as flavone and terpenoids, and can be directly purchased from the market;
the industrial hemp extract and cannabidiol both contain THC, do not contain any banned substances, and can be directly purchased from the market.
In some embodiments, in the above composition, the vegetable oil is one or more of hemp seed oil, sunflower seed oil, olive oil, camellia oil, wheat germ oil, and sweet almond oil, and preferably, the vegetable oil is hemp seed oil.
In some embodiments, the composition comprises the following components in percentage by mass according to utility and cost:
based on the total of the components as 100wt percent.
In some embodiments, the composition of any of the above, wherein the industrial cannabis extract or cannabidiol is present in an amount of, for example, 5 wt%, 6 wt%, 7 wt%, 8 wt%.
In some embodiments, in any of the above compositions, the vitamin E can be present in an amount of, for example, 1 wt%, 2 wt%, 3 wt%, 4 wt%.
In some embodiments, the composition of any one of the above, wherein the retinol is present in an amount of 1 wt%, 2 wt%, 3 wt%, for example.
In some embodiments, the composition of any one of the above, wherein the soy lecithin is present in an amount of, for example, 2 wt%, 3 wt%, 4 wt%.
In some embodiments, the composition of any of the above, the coenzyme Q10 can be present in an amount of, for example, 2 wt%, 3 wt%, 4 wt%.
In some embodiments, in any one of the above compositions, the composition comprises the following components in percentage by mass:
based on the total of the components as 100wt percent.
In some embodiments, in any of the above compositions, the composition further comprises one or more of peony seed oil, lemon peel oil, sea buckthorn fruit oil, and grape seed oil.
In some embodiments, the composition comprises the following components in percentage by mass according to utility and cost:
based on the total of the components as 100wt percent.
In some embodiments, in any of the above compositions, the peony seed oil may be present in an amount of, for example, 1 wt%, 2 wt%, 3 wt%, 4 wt%.
In some embodiments, the composition of any of the above, wherein the lemon peel oil is present in an amount of, for example, 1 wt%, 2 wt%, 3 wt%, 4 wt%.
In some embodiments, in any one of the above compositions, the content of the seabuckthorn fruit oil may be, for example, 1 wt%, 2 wt%, 3 wt%, 4 wt%.
In some embodiments, in any one of the above compositions, the grape seed oil may be present in an amount of, for example, 1 wt%, 2 wt%, 3 wt%, 4 wt%.
In some embodiments, in any one of the above compositions, the composition comprises the following components in percentage by mass:
the sum of the above components is 100 wt%.
In some embodiments, in any one of the above compositions, the composition comprises the following components in percentage by mass:
the sum of the above components is 100 wt%.
In some embodiments, in any one of the above compositions, the composition comprises the following components in percentage by mass:
based on 100 wt% of the total mass of the composition.
In some embodiments, in any one of the above compositions, the composition comprises the following components in percentage by mass:
based on 100 wt% of the total mass of the composition.
In some embodiments, in any one of the above compositions, the composition comprises the following components in percentage by mass:
based on 100 wt% of the total mass of the composition.
In another aspect, the present invention also provides a method for preparing the composition as described in any one of the above, comprising the steps of adding the components other than the vegetable oil to the vegetable oil, and dissolving the components to be clear by heating and stirring at 55 to 60 ℃.
In another aspect, the present invention also provides a soft capsule consisting of a capsule shell and contents filled in the capsule shell, the contents comprising a therapeutically effective amount of the composition as described in any one of the above.
In some embodiments, in the above soft capsules, the capsule shell is a gelatin soft capsule shell.
In another aspect, the present invention also provides a process for preparing the soft capsule as described in any of the above, comprising the steps of adding the components except the vegetable oil to the vegetable oil, heating and stirring at 55-60 ℃ to dissolve until clear, and filling into the capsule shell.
In another aspect, the present invention also provides the use of any of the above compositions and/or any of the above soft capsules in the preparation of any of the following:
1) an antioxidant product;
2) products for repairing skin lighting damage;
3) products for preventing or treating skin inflammation;
4) an anti-aging product;
5) products for improving sleep;
6) products for regulating endocrine function;
7) a product for improving immunity.
The conditioner composition has the advantages that the main components in the conditioner composition have a synergistic effect after compatibility, the bioavailability is high, the oxidation resistance is obviously improved, the anti-aging effect is good, the skin inflammation can be effectively relieved, the skin photodamage can be repaired, the endocrine can be regulated, the sleep can be improved, the stability is good, the conditioner composition is safe and has no toxic or side effect, the conditioner composition can be used for a long time, the skin can be nourished and delayed by external application, the skin inflammation can be effectively relieved, the skin photodamage can be relieved, the endocrine can be regulated, the immunity of the organism can be improved by internal administration, and the free radicals in the body can be inhibited and eliminated. The composition of the present invention can be used as a conditioner for a long period of time.
Detailed Description
The experimental procedures used in the following examples are all conventional procedures unless otherwise specified.
Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
The present invention will be further described with reference to the following examples. It should be understood that the following examples are illustrative only and are not intended to limit the scope of the present invention.
The wide spectrum cannabis oil and cannabidiol are self-prepared samples in laboratories of Yunnan Han union pharmaceutical Co.
Example 1
Weighing 8g of broad spectrum hemp oil, 1g of vitamin E, 2g of retinol, 2g of soybean lecithin, 2g of coenzyme Q10 and 85g of hemp seed oil, sequentially adding the weighed broad spectrum hemp oil, vitamin E, retinol, soybean lecithin and coenzyme Q10 into the hemp seed oil, heating at 55-60 ℃ for 3h, stirring and dissolving until the mixture is clear, and filling the mixture into gelatin soft capsule shells, wherein each capsule is 0.58 g.
Example 2
Weighing 5g of broad-spectrum hemp oil, 4g of vitamin E, 0.1g of retinol, 0.1g of soybean lecithin, 4g of coenzyme Q10, 3g of peony seed oil and 83.8g of hemp seed oil, sequentially adding the weighed broad-spectrum hemp oil, vitamin E, retinol, soybean lecithin, coenzyme Q10 and peony seed oil into the hemp seed oil, heating for 3 hours at 55-60 ℃, stirring and dissolving to be clear, and filling into a gelatin soft capsule shell, wherein each capsule is 0.58 g.
Example 3
Weighing 10g of cannabidiol, 0.1g of vitamin E, 5g of retinol, 5g of soybean lecithin, 0.1g of coenzyme Q10, 4.8g of lemon peel oil and 75g of hemp seed oil, sequentially adding the weighed cannabidiol, vitamin E, retinol, soybean lecithin, coenzyme Q10 and lemon peel oil into the hemp seed oil, heating at 55-60 ℃ for 3h, stirring and dissolving until the mixture is clear, and filling the mixture into a gelatin soft capsule shell, wherein each capsule is 0.58 g.
Example 4
Weighing 10g of broad spectrum hemp oil, 5g of vitamin E, 5g of retinol, 5g of soybean lecithin, 5g of coenzyme Q10, 5g of lemon peel oil and 65g of hemp seed oil, sequentially adding the weighed broad spectrum hemp oil, vitamin E, retinol, soybean lecithin, coenzyme Q10 and lemon peel oil into the hemp seed oil, heating at 55-60 ℃ for 3h, stirring and dissolving until the mixture is clear, and filling the mixture into a gelatin soft capsule shell, wherein each capsule is 0.58 g.
Example 5
Weighing 5g of cannabidiol, 1g of vitamin E, 1g of retinol, 1g of soybean lecithin, 1g of coenzyme Q10, 1g of peony seed oil and 90g of hemp seed oil, sequentially adding the weighed cannabidiol, vitamin E, retinol, soybean lecithin, coenzyme Q10 and peony seed oil into the hemp seed oil, heating at 55-60 ℃ for 3h, stirring and dissolving until the mixture is clear, and filling the mixture into a gelatin soft capsule shell, wherein each capsule is 0.58 g.
Example 6
Weighing 8g of cannabidiol, 1g of vitamin E, 2g of retinol, 4g of soybean lecithin, 0.1g of coenzyme Q10, 3g of seabuckthorn fruit oil and 81.9g of hemp seed oil, sequentially adding the weighed cannabidiol, vitamin E, retinol, soybean lecithin, coenzyme Q10 and seabuckthorn fruit oil into the hemp seed oil, heating for 3 hours at 55-60 ℃, stirring and dissolving until the mixture is clear, and filling the mixture into a gelatin soft capsule shell, wherein each capsule is 0.58 g.
Comparative example 1
Weighing 7g of vitamin E, 7g of retinol, 7g of soybean lecithin, 7g of coenzyme Q10, 7g of lemon peel oil and 65g of hemp seed oil, sequentially adding the weighed vitamin E, retinol, soybean lecithin, coenzyme Q10 and lemon peel oil into the hemp seed oil, heating at 55-60 ℃ for 3h, stirring and dissolving until the mixture is clear, and filling the mixture into a gelatin soft capsule shell with 0.58g per capsule.
Comparative example 2
Weighing 11g of broad spectrum hemp oil, 6g of retinol, 6g of soybean lecithin, 6g of coenzyme Q10, 6g of lemon fruit peel oil and 65g of hemp seed oil, sequentially adding the weighed broad spectrum hemp oil, retinol, soybean lecithin, coenzyme Q10 and lemon fruit peel oil into the hemp seed oil, heating at 55-60 ℃ for 3h, stirring and dissolving until the mixture is clear, and filling the mixture into a gelatin soft capsule shell with 0.58g per capsule.
Comparative example 3
Weighing 15g of broad-spectrum hemp oil, adding into 65g of hemp seed oil, heating at 55-60 deg.C for 3h, stirring to dissolve until clear, and filling into gelatin soft capsule shell of 0.58 g/capsule.
Comparative example 4
Weighing 35g of vitamin E, adding into 65g of hemp seed oil, heating at 55-60 ℃ for 3h, stirring to dissolve until the mixture is clear, and filling into gelatin soft capsule shells of 0.58 g/capsule.
Comparative example 5
Weighing 12g of broad-spectrum hemp oil and 15g of vitamin E, adding into 65g of hemp seed oil, heating at 55-60 ℃ for 3h, stirring to dissolve until the mixture is clear, and filling into gelatin soft capsule shells at 0.58 g/capsule.
Test example 1 evaluation of antioxidant Properties
Preparing the contents of the soft capsules prepared in examples 1-6 and comparative examples 1-5 into ethanol solutions with different concentrations (each sample is prepared into the concentration of 6, 10, 15, 20, 25 and 50 mu g/mL), respectively adding 2.0mL of the prepared sample to be tested into a test tube with a plug, adding 2.0mL of 0.2mmol/L DPPH solution, shaking uniformly, reacting in a dark place for 30min, and measuring the absorbance A1 at 517nm by using absolute ethyl alcohol as a reference; and simultaneously measuring the absorbance A0 of a mixed solution of 2.0mL of 0.2mmol/L DPPH solution and 2.0mL of absolute ethyl alcohol and the absorbance A2 of a mixed solution of 2.0mL of a sample to be measured and 2.0mL of absolute ethyl alcohol. The measurement results are expressed as clearance (E) and are calculated by the formula: e ═ 1- (a 1-a 2) ]/a0 × 100%. And drawing a curve for eliminating DPPH & of the sample to be detected by taking the concentration of the sample to be detected as an abscissa and the elimination rate value as an ordinate, and calculating the concentration of the sample to be detected when the DPPH & elimination rate is 50% according to a linear regression equation of the curve, wherein the concentration is defined as a half inhibition concentration (IC 50). The DPPH-removing ability of the samples was measured by the IC50 value of the sample concentration with a removing rate of 50%, and the results are shown in Table 1.
TABLE 1 comparison of DPPH scavenging ability of samples
As can be seen from Table 1, the compositions of examples 1-6 all have very good radical scavenging effect, while the compositions of comparative examples 1-5 have a certain radical scavenging effect, but the effect is significantly less than that of the compositions of examples 1-6. Particularly, in comparative examples 3 and 4, the radical scavenging action is remarkably reduced compared with other examples and comparative examples, which shows that the antioxidant activity of the cannabidiol after being combined with vitamin E is enhanced, particularly the antioxidant activity of the cannabidiol after being combined with other components in the composition is stronger, and the synergistic effect of the components of the composition after being combined is shown.
Test example 2 animal experiment for repairing photodamage
Removing hair from back of mouse (ICR mouse, purchased from animal experiment center of Zhejiang university of traditional Chinese medicine, body weight 20 + -5 g), exposing skin of back sufficiently, and performing UVB (300 mJ/cm)2) Irradiating the mice once a day for 3 days continuously, finishing molding, and enabling the back skin of the successfully molded mice to have obvious erythema and scale change.
The successfully modeled mice were divided into 10 groups of 10 mice each, and each group of mice was administered with the contents of the soft capsules prepared in examples 1 to 6 and comparative examples 1 to 5, and the contents of the soft capsules were applied to the injured skin of the back of the mice by 1ml each day in the morning and evening, and administered for two weeks.
Skin damage status was scored on UVB-irradiated areas of the backs of the mice (see table 2 for details), and the results are shown in table 3.
TABLE 2 evaluation criteria for skin damage status of UVB-irradiated area of mouse back
TABLE 3 mice dorsal skin injury status score
As can be seen from the results in table 3, the compositions of examples 1 to 6 of the present invention have better photo-repairing effects than the composition of the comparative example, indicating that the photo-damage repairing effect is enhanced after the cannabidiol or the cannabis oil of the broad spectrum is combined with other components, and the synergistic effect is obtained.
Claims (10)
1. A composition comprising industrial cannabis extract or cannabidiol, vitamin E, retinol, soy lecithin, coenzyme Q10, and vegetable oil.
4. The composition according to any one of claims 1 to 3, characterized in that: the vegetable oil is one or more of hemp seed oil, sunflower seed oil, olive oil, camellia oil, wheat germ oil and sweet almond oil;
preferably, the vegetable oil is hemp seed oil.
5. The composition according to any one of claims 1 to 4, characterized in that: the industrial hemp extract contains 30-99% of cannabidiol by mass percentage;
preferably, the industrial hemp extract contains 50-99% of cannabidiol by mass percentage;
preferably, the industrial cannabis extract is a broad spectrum of cannabis oils.
6. The composition of claim 1, wherein: the composition further comprises one or more of peony seed oil, lemon peel oil, sea buckthorn fruit oil, and grape seed oil.
8. A soft capsule comprised of a capsule shell and contents filled in the capsule shell, the contents comprising a therapeutically effective amount of the composition of any one of claims 1-7.
9. The soft capsule according to claim 8, characterized in that: the capsule shell is a gelatin soft capsule shell.
10. Use of a composition according to any one of claims 1 to 7 and/or a soft capsule according to claim 8 or 9 for the preparation of a product according to any one of the following:
1) an antioxidant product;
2) products for repairing skin lighting damage;
3) products for preventing or treating skin inflammation;
4) an anti-aging product;
5) products for improving sleep;
6) products for regulating endocrine function;
7) a product for improving immunity.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911405762.9A CN111956535A (en) | 2019-12-30 | 2019-12-30 | Conditioner composition and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911405762.9A CN111956535A (en) | 2019-12-30 | 2019-12-30 | Conditioner composition and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111956535A true CN111956535A (en) | 2020-11-20 |
Family
ID=73358320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911405762.9A Pending CN111956535A (en) | 2019-12-30 | 2019-12-30 | Conditioner composition and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111956535A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114642699A (en) * | 2020-12-18 | 2022-06-21 | 北京红惠新医药科技有限公司 | Essential oil composition containing cannabis leaf extract and preparation method and application thereof |
CN116036146A (en) * | 2021-10-28 | 2023-05-02 | 云南汉盟制药有限公司 | Composition for preventing or treating radiation injury, application and product thereof |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150245991A1 (en) * | 2014-02-28 | 2015-09-03 | HDDC Holdings, LLC | Anti-aging dermal composition comprising herbal extracts |
US20160235661A1 (en) * | 2015-02-16 | 2016-08-18 | Axim Biotechnologies, Inc. | Cosmetic and topical compositions comprising cannabigerol |
WO2018152334A1 (en) * | 2017-02-15 | 2018-08-23 | Molecular Infusions, Llc | Formulations |
WO2019036243A1 (en) * | 2017-08-16 | 2019-02-21 | Molecular Infusions, Llc | Formulations |
CN109419851A (en) * | 2017-08-25 | 2019-03-05 | 汉义生物科技(北京)有限公司 | Cannador or cannabidiol are dispelling the application in cicatrix of skin |
CN110051568A (en) * | 2019-05-29 | 2019-07-26 | 广州恒雅生物化工有限公司 | Anti-ageing composition, anti-ageing cream and preparation method thereof |
CN110215443A (en) * | 2019-07-08 | 2019-09-10 | 云南绿新生物药业有限公司 | A kind of anti-aging, the preparation method for improving sleep soft capsule |
CN110496075A (en) * | 2019-06-20 | 2019-11-26 | 昆药集团股份有限公司 | A kind of composition with repair function of releiving and preparation method thereof, preparation and application |
CN110559229A (en) * | 2019-09-21 | 2019-12-13 | 云南辰锦威生物科技有限公司 | Night cream containing cannabidiol CBD nano-emulsion and preparation method thereof |
-
2019
- 2019-12-30 CN CN201911405762.9A patent/CN111956535A/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150245991A1 (en) * | 2014-02-28 | 2015-09-03 | HDDC Holdings, LLC | Anti-aging dermal composition comprising herbal extracts |
US20160235661A1 (en) * | 2015-02-16 | 2016-08-18 | Axim Biotechnologies, Inc. | Cosmetic and topical compositions comprising cannabigerol |
WO2018152334A1 (en) * | 2017-02-15 | 2018-08-23 | Molecular Infusions, Llc | Formulations |
WO2019036243A1 (en) * | 2017-08-16 | 2019-02-21 | Molecular Infusions, Llc | Formulations |
CN109419851A (en) * | 2017-08-25 | 2019-03-05 | 汉义生物科技(北京)有限公司 | Cannador or cannabidiol are dispelling the application in cicatrix of skin |
CN110051568A (en) * | 2019-05-29 | 2019-07-26 | 广州恒雅生物化工有限公司 | Anti-ageing composition, anti-ageing cream and preparation method thereof |
CN110496075A (en) * | 2019-06-20 | 2019-11-26 | 昆药集团股份有限公司 | A kind of composition with repair function of releiving and preparation method thereof, preparation and application |
CN110215443A (en) * | 2019-07-08 | 2019-09-10 | 云南绿新生物药业有限公司 | A kind of anti-aging, the preparation method for improving sleep soft capsule |
CN110559229A (en) * | 2019-09-21 | 2019-12-13 | 云南辰锦威生物科技有限公司 | Night cream containing cannabidiol CBD nano-emulsion and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
关志宇主编: "《药物制剂辅料与包装材料》", 31 January 2017, 北京:中国医药科技出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114642699A (en) * | 2020-12-18 | 2022-06-21 | 北京红惠新医药科技有限公司 | Essential oil composition containing cannabis leaf extract and preparation method and application thereof |
CN116036146A (en) * | 2021-10-28 | 2023-05-02 | 云南汉盟制药有限公司 | Composition for preventing or treating radiation injury, application and product thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Agte et al. | The importance of nutrition in the prevention of ocular disease with special reference to cataract | |
US20030175235A1 (en) | Bioactive botanical cosmetic compositions and processes for their production | |
CN106310233A (en) | Nutrient composition and health food capable of preventing oxidation, reliving fatigue and alcoholism, removing spots and heavy metals, whitening skin, and moisturizing | |
CN111956535A (en) | Conditioner composition and preparation method and application thereof | |
CN105213261A (en) | A kind of black fruit matrimony vine oxidation resistant skin care item | |
CN112493480A (en) | Antioxidant composition and application thereof | |
Ahmed et al. | Diet and skin health: The good and the bad | |
CN112156143B (en) | Compound nutrient composition with antioxidant function | |
KR20120119976A (en) | An agent for enhancing the expression of redox-associated factors | |
JP2015027998A (en) | Moisturizer, skin barrier function activator, tight junction formation accelerator, trpv4 expression enhancer, intracellular calcium concentration increaser, intracellular calcium concentration increaser, lipid synthesis accelerator, blood flow improver and periocular darkness ameliorator | |
CN113876626A (en) | Composition with protective effect on skin cell damage induced by blue light and application of composition in cosmetics | |
WO2015015816A1 (en) | Fibroblast activator | |
KR20170011035A (en) | Cosmetic composition for preventing thermal skin aging containing aloe vera leaves complex extract | |
AU2010241716B2 (en) | Oral compositions for skin benefits | |
KR102585685B1 (en) | Composition for protecting or improving UV-induced skin damage comprising the extract of plants as an active ingredient | |
EP3991801A1 (en) | Composition for improving skin condition containing plant extracts | |
Williams et al. | An oral antioxidant formulation delaying and potentially reversing | |
KR102172316B1 (en) | A composition comprising rose flower extract for reducing body fat and a health functional food comprising the composition | |
Jain et al. | An Overview Of Medicinal Plants Used For Anti-Aging Face Pack Formulation | |
CN105213274A (en) | The near-nature forest skin care item of natural plant nutrient and Growth of Cells reparative factor | |
CN112843155B (en) | Composition suitable for puerpera and used for removing freckles and relieving lumbago | |
CN116270349B (en) | Composition, preparation method and application thereof | |
WO2015015815A1 (en) | Fibroblast activator | |
Szumny et al. | Extract from Aronia melanocarpa, Lonicera caerulea, and Vaccinium myrtillus Improves near Visual Acuity in People with Presbyopia | |
CN108606313A (en) | A kind of combination lozenge and preparation method thereof for alleviating visual fatigue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201120 |
|
RJ01 | Rejection of invention patent application after publication |